Fibroblasts and iPSCs derived from PD patients with LRRK2 mutations also show impairment in general mitochondrial function, including increased oxidative damage, reduced mitochondrial membrane potential, and reduced ATP production (Mortiboys et al., 2010; Sanders et al., 2014). The gene discussed is LRRK2; the disease is Parkinson disease.